Growth factor production by arterial and vein grafts: relevance to coronary artery bypass grafting

A V Sterpetti1, A Cucina, B Randone

  • 1Department of Surgery, University of Rome-La Sapienza, Italy.

Surgery
|September 1, 1996
PubMed

Insights

Arterial grafts produce less platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) than vein grafts. This lower production may explain why arterial grafts resist atherosclerosis and vein grafts develop myointimal hyperplasia.

Area of Science:

  • Vascular biology
  • Surgical research
  • Biomedical engineering

Background:

  • Saphenous vein grafts often fail late due to myointimal hyperplasia and atherosclerosis.
  • Internal mammary artery grafts show resistance to atherosclerosis.
  • Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) are implicated in hyperplasia and atherosclerosis.

Purpose of the Study:

  • To compare the production of PDGF and bFGF in arterial versus vein grafts.
  • To investigate the role of growth factors in graft failure mechanisms.

Main Methods:

  • Interposition of arterial and vein grafts in Lewis rats.
  • Organ culture of grafts in serum-free media.
  • Measurement of PDGF and bFGF production and mitogenic activity.

Main Results:

  • Arterial grafts produced significantly less PDGF and bFGF compared to vein grafts (p < 0.01).
  • Vein grafts exhibited higher mitogenic activity in conditioned media (p < 0.001).
  • Significant myointimal hyperplasia was observed in all vein grafts.

Conclusions:

  • Lower PDGF and bFGF production by arterial grafts may contribute to their resistance to atherosclerosis.
  • This finding helps explain the lower incidence of atherosclerotic changes in internal mammary artery bypass grafts.
Abstract

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...